JP4476626B2 - 抗細菌性を有するアンドルイミドおよびモイルアミドｂの誘導体 - Google Patents

抗細菌性を有するアンドルイミドおよびモイルアミドｂの誘導体 Download PDF

Info

Publication number
JP4476626B2
JP4476626B2 JP2003545619A JP2003545619A JP4476626B2 JP 4476626 B2 JP4476626 B2 JP 4476626B2 JP 2003545619 A JP2003545619 A JP 2003545619A JP 2003545619 A JP2003545619 A JP 2003545619A JP 4476626 B2 JP4476626 B2 JP 4476626B2
Authority
JP
Japan
Prior art keywords
alkyl
group
aryl
substituents
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2003545619A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005514361A5 (https=
JP2005514361A (ja
Inventor
ニーナ・ブルンナー
クリストフ・フライベルク
トーマス・ランペ
ベン・ニュートン
ミヒャエル・オッテネーダー
ヨーゼフ・ペルナーシュトルファー
イェンス・ポールマン
グイド・シッファー
満之 島田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Bayer Schering Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma AG filed Critical Bayer Schering Pharma AG
Publication of JP2005514361A publication Critical patent/JP2005514361A/ja
Publication of JP2005514361A5 publication Critical patent/JP2005514361A5/ja
Application granted granted Critical
Publication of JP4476626B2 publication Critical patent/JP4476626B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
JP2003545619A 2001-11-20 2002-11-07 抗細菌性を有するアンドルイミドおよびモイルアミドｂの誘導体 Expired - Lifetime JP4476626B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10156894A DE10156894A1 (de) 2001-11-20 2001-11-20 Harnstoffe
PCT/EP2002/012428 WO2003043982A1 (de) 2001-11-20 2002-11-07 Derivate von andrimid und moiramid b mit antibakteriellen eigenschaften

Publications (3)

Publication Number Publication Date
JP2005514361A JP2005514361A (ja) 2005-05-19
JP2005514361A5 JP2005514361A5 (https=) 2006-01-05
JP4476626B2 true JP4476626B2 (ja) 2010-06-09

Family

ID=7706325

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003545619A Expired - Lifetime JP4476626B2 (ja) 2001-11-20 2002-11-07 抗細菌性を有するアンドルイミドおよびモイルアミドｂの誘導体

Country Status (8)

Country Link
US (1) US7544709B2 (https=)
EP (1) EP1448521B1 (https=)
JP (1) JP4476626B2 (https=)
AU (1) AU2002366192A1 (https=)
CA (1) CA2467471C (https=)
DE (2) DE10156894A1 (https=)
ES (1) ES2250745T3 (https=)
WO (1) WO2003043982A1 (https=)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4868203A (en) * 1986-06-02 1989-09-19 Kabushikikaisha Ueno Seiyaku Oyo Kenkyujo Bacterial substance and pharmaceutical composition thereof
JPH01301657A (ja) * 1988-05-28 1989-12-05 Suntory Ltd 新規アンドリミド誘導体
JP2004501191A (ja) * 2000-06-28 2004-01-15 テバ　ファーマシューティカル　インダストリーズ　リミティド カルベジロール

Also Published As

Publication number Publication date
EP1448521B1 (de) 2005-09-28
DE50204419D1 (de) 2006-02-09
CA2467471A1 (en) 2003-05-30
EP1448521A1 (de) 2004-08-25
US7544709B2 (en) 2009-06-09
AU2002366192A1 (en) 2003-06-10
DE10156894A1 (de) 2003-05-28
US20050080129A1 (en) 2005-04-14
WO2003043982A1 (de) 2003-05-30
ES2250745T3 (es) 2006-04-16
JP2005514361A (ja) 2005-05-19
CA2467471C (en) 2011-05-10

Similar Documents

Publication Publication Date Title
AU739511B2 (en) N-aroylphenylalanine derivatives
KR20020029908A (ko) 무티린 유도체 및 항균제로서의 그의 용도
JP4437078B2 (ja) 抗菌性アミドマクロサイクル
SK49194A3 (en) Urethanes and ureas which are inducing production of cytokine
DE10358824A1 (de) Antibakterielle Makrozyklen mit substituiertem Biphenyl
DE10208256A1 (de) Piperidinouracile
EP1526896A1 (de) Antibakterielle ester-makrozyklen
DE102005014245A1 (de) Antibakterielle Amid-Makrozyklen V
JP4476626B2 (ja) 抗細菌性を有するアンドルイミドおよびモイルアミドｂの誘導体
US20090149528A1 (en) Cinnamic acid amides
KR20050089070A (ko) 로타마제 억제용 화합물
JP4528122B2 (ja) アリールアミド類
JP6125425B2 (ja) 微生物によって媒介される疾患の治療に用いるプレウロムチリン誘導体
JP2006522054A (ja) 結晶性ｎ−ホルミルヒドロキシルアミン化合物
DE10243201A1 (de) Alkyl- und Alkenylamide
DE10326918A1 (de) Substituierte Alkylamide
IL165630A (en) Antibacterial amide macrocycles
DE10162745A1 (de) Heterocyclylaminocarbonyluracile

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051102

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20051102

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090616

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090915

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20091020

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20091020

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20091020

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100128

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100223

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100310

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130319

Year of fee payment: 3

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130319

Year of fee payment: 3

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350